Background: Evidence suggests that primary prophylaxis with filgras:m (Neupogen®, administered daily for 10--11 days per chemotherapy cycle) is equally effec:ve as pegfilgras:m (Neulasta®, administered once per chemotherapy cycle) in preven:ng febrile neutropenia. Economic evalua:ons (EEs) may be used to guide decisions in resource alloca:on.
Conclusions
• A structured literature search was performed in the EMBASE, MEDLINE, Cochrane Library, Google Scholar, ABI/Inform, and the Web of Science databases.
• Inclusion criteria were primary research in pa:ents with solid tumor cancer; specifically, studies comparing filgras:m and pegfilgras:m, resul:ng in full manuscripts published in English language.
• Concepts of the search included "filgras:m," "pegfilgras:m," "cost analysis,"
and "economic evalua:on." • The resul:ng abstracts were evaluated by the inclusion criteria first and then in full--text format by two reviewers (DS, AA).
• When the reviewers ques:oned the inclusion of an ar:cle, the research team decided via consensus.
• The reviewers independently abstracted the data from each ar:cle into an extrac:on spreadsheet.
• The type of economic evalua:on was captured and categorized as a cost--effec:veness analysis (CEA) if the monetary units were compared with a health outcome, a cost--u:lity analysis (CUA) if the monetary units were compared with a preference--based u:lity, or a cost--benefit analysis (CBA) if results were presented as a willingness to pay for the treatment.
• Incremental cost effec:veness ra:os (ICERs), a measure of the addi:onal cost for an addi:onal unit of outcome, were iden:fied if they were included in the ar:cle.
• A quality assessment of the methodology was performed on the included studies by using the Drummond Checklist 12 for assessing economic evalua:ons.
• This checklist iden:fies 10 key elements and methodological characteris:cs that are expected in a well--executed study.
• We gave each item a score of 1 for "yes" and 0 for "no" or "can't tell."
• A higher quality study was defined as a score of >7.
• A single reviewer scored all the ar:cles because it was established that a single reviewer could be enough to perform the quality assessment with the checklist accurately and quickly.
Background
• Febrile neutropenia (FN), defined as the presence of both grade 4 neutropenia and fever, is a major toxicity of cancer chemotherapy and rou:nely results in dose delays or reduc:ons. 1 • Prophylac:c use of granulocyte--colony s:mula:ng factors (G--CSFs) aier chemotherapy can decrease the incidence of FN and its associated mortality, morbidity, and cost. • These five manufacturer--sponsored studies suggest that pegfilgras:m is cost--saving compared to 11--day filgras:m but not to 6--day filgras:m.
• The drug costs used in calcula:ons did not correspond to actual market prices thus skewing results.
• Studies independent of industry sponsor are needed to make conclusive interpreta:ons.
• Major limita:on of the present review is the small number of studies; more data is necessary to understand the impact of these agents.
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